Gene · 5710
PSMD4: proteasome 26S subunit ubiquitin receptor, non-ATPase 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMD4: proteasome 26S subunit ubiquitin receptor, non-ATPase 4. Genes, record 5710. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5710
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P55036 | 26S proteasome non-ATPase regulatory subunit 4 | 377 | 133 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 8525 | P55036 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8525 | P55036 | Espacenet |
| JP 2025038035 A | 2025-03-18 | 4458 | P55036 | Espacenet |
| US 12134655 B2 | 2024-11-05 | 4458 | P55036 | Espacenet |
| US 11694765 B2 | 2023-07-04 | 302 | P55036 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 6198 | P55036 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67776 | P55036 | Espacenet |
| JP 2022534270 A | 2022-07-28 | 31 | P55036 | Espacenet |
| JP 2022530667 A | 2022-06-30 | 4458 | P55036 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170747 | P55036 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,229
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,229
See all 1,229 trialsNIH grants954
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMD4 papers | Newest fiscal year |
|---|---|---|---|
| ZIABC011490 | Maintaining cell health by targeted protein degradation | 17 | 2025 |
| R01GM065334 | Solution structure and dynamics of polyubiquitin chains | 14 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 3 | 2025 |
| P30GM124165 | NE-CAT: A Resource for Advanced Macromolecular Crystallography | 3 | 2025 |
| P50CA098252 | SPORE in Cervical Cancer | 3 | 2025 |
1 to 10 of 954Source NIH's project files
See all 954 nih grantsPapers1,432
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A multi-region transcriptomic framework reveals global and region-specific ubiquitin-proteasome system biomarkers in Alzheimer's disease. | Funct Integr Genomics | 2026 | 42809130 | PubTator, text mining | PubMed |
| Functional Engineered Exosomes Loaded with Nanoenzymes Targeting the Proteasome and Inflammation for the Treatment of Rheumatoid Arthritis. | Small | 2026 | 42522687 | PubTator, text mining | PubMed |
| Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy. | Mol Cell | 2026 | 42476128 | PubTator, text mining | PubMed |
| Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease. | Biochem Pharmacol | 2026 | 42398870 | PubTator, text mining | PubMed |
| PSMD4 promotes malignant phenotypes and is associated with angiogenesis-related signaling and immune remodeling in hepatocellular carcinoma. | Discov Oncol | 2026 | 42262718 | PubTator, text mining | PubMed |
| Implication of Epigenetic Alterations of ZEB1 in Colorectal Cancer (CRC) Pathogenesis and Therapy Development. | Curr Issues Mol Biol | 2026 | 41899428 | PubTator, text mining | PubMed |
| The accessory adapters FAF1, FAF2, and UBXN7 accelerate proteasomal degradation by increasing prior p97-mediated substrate unfolding. | Sci Adv | 2026 | 41790892 | PubTator, text mining | PubMed |
| Physiological and molecular dynamic changes during 23-day high-altitude exposure reveal novel biomarkers for acclimatization. | Front Physiol | 2026 | 41788875 | PubTator, text mining | PubMed |
| The lactate/PSMD4/glycolysis feedback loop drives chemoresistance and immunosuppression in gallbladder cancer. | Sci Bull (Beijing) | 2026 | 41786576 | PubTator, text mining | PubMed |
| SNRPD2-dependency Fuels an Oncogenic Alternative Splicing Repertoire Driving Disease Aggressiveness in Glioma. | Cancer Genomics Proteomics | 2026 | 41771572 | PubTator, text mining | PubMed |
1 to 10 of 1,432
See all 1,432 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5710
GET https://conductscience.org/api/genes/v1/5710/patents?page=2